Clinical Trial: Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07689539) titled 'Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation' on June 21.

Brief Summary: This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Pancreatic Cancer

Intervention: DRUG: DN022150

iv QW 28-day/cycle

DRUG: Chemotherapy

Investigator's Choice of Chemotherapy: nal-IRI + 5-FU/LV, AG, or S-1

Recruitment Status: N...